These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 26343214)

  • 1. Lipid-lowering medications for children and adolescents.
    Miller ML; Wright CC; Browne B
    J Clin Lipidol; 2015; 9(5 Suppl):S67-76. PubMed ID: 26343214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combined treatment: regimens, indications and safety profile].
    Muñiz Grijalvo O; Villar Ortiz J
    Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials.
    Luo J; Huang T; Xu R; Wang X; Yang Y; Li L; Zhang X; Zhang Y; Yang R; Wang J; Yang H; Ma Y; Yang B; Wang T; Jiao L
    BMJ Open; 2022 Sep; 12(9):e061884. PubMed ID: 36691198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    McKenney JM
    Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.
    Zafrir B; Jain M
    Cardiovasc Drugs Ther; 2014 Aug; 28(4):361-77. PubMed ID: 24952127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
    Bittner V; Deng L; Rosenson RS; Taylor B; Glasser SP; Kent ST; Farkouh ME; Muntner P
    J Am Coll Cardiol; 2015 Oct; 66(17):1864-72. PubMed ID: 26493657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric dyslipidemia: recommendations for clinical management.
    Wilson DP; McNeal C; Blackett P
    South Med J; 2015 Jan; 108(1):7-14. PubMed ID: 25580750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid lowering for secondary prevention of cardiovascular disease in older adults.
    Thomas JE; Tershakovec AM; Jones-Burton C; Sayeed RA; Foody JM
    Drugs Aging; 2010 Dec; 27(12):959-72. PubMed ID: 21087066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Currently available hypolipidaemic drugs and future therapeutic developments.
    Farmer JA; Gotto AM
    Baillieres Clin Endocrinol Metab; 1995 Oct; 9(4):825-47. PubMed ID: 8593127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?
    Guyton JR
    Curr Opin Lipidol; 2010 Aug; 21(4):372-7. PubMed ID: 20625257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of lipid-lowering drug therapy in children and adolescents.
    Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.
    Ardoin SP; Sandborg C; Schanberg LE
    Lupus; 2007; 16(8):618-26. PubMed ID: 17711898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
    Milionis H
    Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
    Collins PD; Sattar N
    Curr Cardiol Rep; 2016 Dec; 18(12):133. PubMed ID: 27864787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.